RxSight (RXST) Q2 2025: LDD Sales Drop 49% as Utilization Refocuses Growth Strategy
RxSight’s Q2 revealed a sharp 49% drop in Light Delivery Device (LDD, laser system for lens adjustment) sales and a marked slowdown in overall revenue, prompting a major operational and customer engagement overhaul. Leadership is concentrating on maximizing utilization within its large installed base and realigning resources to stabilize growth, as the company faces persistent softness in new account additions and international ramp is still in its infancy. Investors should watch for tangible signs of improved same-store performance and the impact of the new customer success model in the coming quarters.
Summary
- Installed Base Leverage: RxSight is pivoting focus to utilization growth among existing LDD customers amid sluggish new device sales.
- Margin Resilience: Higher mix of LAL (Light Adjustable Lens, customizable intraocular lens) sales supported gross margin expansion even as top-line growth faltered.
- Execution Watch: Operational realignment and customer success initiatives are critical to restoring growth momentum and achieving cash flow breakeven.
Performance Analysis
Q2 2025 marked a pivotal quarter for RxSight as revenue fell sequentially and year-over-year, driven by a dramatic contraction in LDD sales volumes. The company sold 40 LDD units, down 49% YoY and 45% QoQ, reflecting both market saturation in core accounts and a slower pace of new customer onboarding. LDD revenue now accounts for just 15% of total revenue, a sharp decline from prior periods. In contrast, LAL sales rose 13% YoY and comprised 80% of total revenue, up from 68% last year, reinforcing the shift toward a recurring revenue base centered on consumables. This favorable mix drove gross margin up to 74.9%, but could not offset the drag from lower overall sales.
Operating expenses climbed 19% YoY for SG&A and 23% for R&D, largely due to expanded personnel and stock-based compensation, as well as increased clinical investment to support adoption. The company posted a net loss of $11.8 million, with non-GAAP losses narrowing to $3.2 million after adjusting for stock comp. Cash burn was modest at $1.8 million, leaving RxSight with a robust $227.5 million cash position to support the commercial reset.
- LDD Sales Contraction: The steep drop in LDD sales signals near-term limits to market expansion and underscores the need for deeper account engagement.
- Consumables Mix Shift: LAL revenue growth and higher mix are cushioning margin pressure and anchoring the evolving business model toward recurring revenue.
- Expense Discipline: Sequential stability in SG&A and R&D reflects early efforts to realign cost structure with revised growth expectations.
While the installed base rose 34% YoY, the company’s ability to drive higher utilization per account will determine the pace and durability of future growth.
Executive Commentary
"We have unified our LAL sales and clinical support personnel into a single customer success organization...managing the customer experience from onboarding through long-term utilization growth. These teams leverage proven best practices derived from customers who have already demonstrated strong clinical and commercial success with our technology."
Dr. Ron Kurtz, President and CEO
"Despite gross margin in the first half approaching 75%, we are not adjusting our gross margin guidance higher because we expect lower gross margin in the second half of this year due to higher costs and lower production volume as we have right-sized production quantities consistent with our lower revenue guidance."
Shelley Tunin, Chief Financial Officer
Strategic Positioning
1. Utilization-First Commercial Model
RxSight is executing a decisive pivot from new account acquisition toward maximizing utilization within its existing LDD installed base. The newly unified customer success organization is tasked with onboarding, training, and ongoing support to drive higher LAL use per account, leveraging best practices from top-performing customers. This approach recognizes that future growth will rely as much on deepening penetration within current practices as on expanding the device footprint.
2. Consumables-Led Revenue Mix
The business model is shifting toward recurring revenue from LAL consumables, which now comprise 80% of total sales. This transition offers margin stability and greater predictability, but also means that top-line growth is increasingly tied to utilization rates rather than device placements. Sustained growth will require both higher usage per customer and eventual reacceleration of new account additions.
3. International Expansion—Early Days
Regulatory approvals and initial launches in South Korea and Singapore mark the first steps in RxSight’s international strategy, targeting private pay and premium cataract markets. However, management is clear that meaningful overseas revenue contribution will take time, with major markets like Japan and China still in lengthy regulatory cycles. The company is applying its US playbook abroad, but near-term impact is expected to be modest.
4. R&D and Workflow Innovation
Investment in R&D remains a priority, with a focus on refining postoperative workflows and expanding the clinical utility of the LAL platform. Next-generation capabilities aim to simplify adoption for physicians and broaden patient eligibility, supporting both utilization and differentiation in a competitive premium IOL market.
5. Leadership and Board Augmentation
The addition of Raymond Cohn to the board brings further medtech scaling expertise, reinforcing RxSight’s commitment to disciplined growth and operational rigor during this transitional period.
Key Considerations
Q2 2025 was a reset quarter for RxSight, as management responded to slowing growth by realigning commercial priorities and operational resources. The company’s strong cash position provides a buffer, but the near-term focus will be on proving that utilization initiatives can restore growth and margin leverage.
Key Considerations:
- Same-Store Growth Imperative: With new LDD sales slowing, the ability to drive higher LAL use per existing customer is now the critical growth lever.
- Margin Sustainability: The high-margin LAL consumable mix is supporting gross margin, but lower production volumes in H2 may create headwinds.
- Cash Flow Path: Delayed revenue growth pushes out the timeline to cash flow breakeven, though the company’s margin profile could enable a quick rebound if utilization recovers.
- International Ramp Pace: Overseas expansion is in its infancy, with regulatory wins but limited near-term revenue impact expected.
- Expense Management: SG&A and R&D discipline will be closely watched as RxSight balances investment in growth with the need to protect cash.
Risks
Persistent weakness in new device sales, if not offset by meaningful utilization gains, could create a prolonged growth plateau and delay profitability. Execution risk is high, as the success of the customer success model is unproven at scale. International expansion carries regulatory, adoption, and competitive uncertainties, and macro headwinds or reimbursement changes in the premium IOL market could further pressure performance.
Forward Outlook
For Q3 and Q4 2025, RxSight guided to:
- Total revenue in the range of $120 to $130 million for the full year, reflecting a 7% to 14% decline from 2024.
- Gross margin of 72% to 74%, with H2 expected to be lower than H1 due to reduced volumes and higher costs.
- Operating expense of $145 to $155 million, up 7% to 14% YoY, including $27 to $30 million in stock-based compensation.
Management cited continued softness in LAL adoption and fewer new LDD sales as the main drivers of the revised outlook. The company expects lower revenue in the second half versus the first half, and is not expecting near-term upside from international markets.
- Utilization growth among current accounts is the key variable for hitting the upper end of guidance.
- Further LDD sales weakness would push results toward the low end.
Takeaways
Investors should focus on RxSight’s ability to execute its utilization-driven strategy and monitor for early signals of improved same-store growth. The company’s strong margin profile and cash position provide flexibility, but a sustained rebound will require both operational discipline and evidence that the customer success model can deliver tangible results.
- Growth Engine Reset: With new device sales slowing, RxSight’s fate now hinges on driving higher LAL usage per installed customer—a shift that will test the scalability and effectiveness of its new commercial approach.
- Margin and Cash Levers: The consumables mix is a margin tailwind, but expense discipline and working capital management will be crucial as revenue remains under pressure.
- International and Innovation Watch: Overseas expansion and R&D-driven workflow improvements are long-term levers, but are unlikely to offset near-term US softness in the next several quarters.
Conclusion
RxSight’s Q2 was a wake-up call, forcing a strategic pivot to utilization and customer engagement as the key to future growth. The coming quarters will reveal whether the new model can restore momentum or if deeper challenges persist in the premium IOL adoption curve.
Industry Read-Through
RxSight’s experience highlights the challenges of scaling disruptive medtech platforms in procedure-driven markets, especially once early adopter momentum fades. The pivot to a customer success model and focus on utilization may become a playbook for other device companies facing saturation in core segments. Margin resilience through consumables mix is a key lesson for peers, but also underscores the risk of top-line stagnation if device placements slow. International expansion remains a long game, with regulatory timelines and market development requiring patience and disciplined investment.